GeoVax Labs (GOVX) Projected to Post Earnings on Thursday

GeoVax Labs (NASDAQ:GOVX) is projected to announce its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $2.38 million for the quarter.

GeoVax Labs Price Performance

NASDAQ GOVX opened at $1.48 on Thursday. The company has a 50 day simple moving average of $2.03 and a 200-day simple moving average of $2.66. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

Analysts Set New Price Targets

A number of analysts have recently issued reports on GOVX shares. Alliance Global Partners started coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of GeoVax Labs in a research report on Friday, November 15th. Finally, D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.20.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.